Clinical trials: Post COVID-19 Cognitive Impairment
Post-Acute COVID-19 Syndrome, Cognitive Impairment
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute…
- Conditions
- Post-Acute COVID-19 Syndrome, Cognitive Impairment, Neurological Complication
- Trial name
- NCT05947617
- Testing
- VIX001
- Volunteers
- 9 people
- Sponsor
- Neobiosis, LLC
Post COVID-19 Condition (PCC)
Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy
The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved.
- Trial name
- BALCoS/DiLCoS (NCT05781893)
- Testing
- Digital intervention (DiLCoS), Data collection
- Where
- Switzerland
- Volunteers
- 196 people
- Sponsor
- University Hospital, Basel, Switzerland
PostCovid
Interprofessional Rehabilitation for Patients With Post-COVID Condition
Since 2020, millions of individuals have been infected with SARS-CoV-2 virus and a substantial proportion continue to experience persistent symptoms that impair functional capacity, limit daily activities, and negatively affect…
- Trial name
- Post-COVID (NCT07821385)
- Testing
- Interprofessional cognitive group rehabilitation
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Danderyd Hospital
Cognitive Impairment
Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment
This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment.
- Trial name
- NCT05498493
- Testing
- Cognitive Rehabilitation, Brain Health Education Program
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Post-COVID-19 Condition, Post-COVID-19 Syndrome
Vortioxetine for Post-COVID-19 Condition
A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after…
- Conditions
- Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
- Trial name
- NCT05047952
- Testing
- Vortioxetine
- Where
- Canada
- Volunteers
- 149 people
- Sponsor
- Brain and Cognition Discovery Foundation
Post-COVID Syndrome
Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.
Although most infected people survive the infection, many have persistent sequelae or symptoms, which cause disability or decreased quality of life.
- Trial name
- REHABCOVID (NCT05846126)
- Testing
- RehabCovid_Telematic, RehabCovid_ImmersiveVR, Control_Condition
- Where
- Spain
- Volunteers
- 172 people
- Sponsor
- Consorci Sanitari de Terrassa
Covid19, Respiratory Disease
Post COVID19 Functional and Cognitive Assessments
The main objective of the proposed study is to evaluate the impact of coronavirus (2019-nCoV), hereafter COVID -19, on patients' loss of functional capacity after completion of hospital treatment.
- Conditions
- Covid19, Respiratory Disease, Walking, Difficulty, Cognitive Decline
- Trial name
- PostCovidZRS (NCT04860206)
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Science and Research Centre Koper
Post-Acute COVID-19, Post-Acute COVID-19 Syndrome
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC).
- Conditions
- Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID
- Trial name
- NCT06156202
- Testing
- Comprehensive Rehabilitation, Augmented Usual Care
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Pennsylvania
Traumatic Brain Injury, Fatigue
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth…
- Conditions
- Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
- Trial name
- NCT03554265
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Post COVID-19, Cognitive Dysfunction
Multimodal Investigation of Post COVID-19 in Females
The purpose of this study is to investigate the effects of transcutaneous vagus nerve stimulation (t-VNS) on Long Covid symptoms in females and to identify factors influencing susceptibility and recovery-particularly in the…
- Trial name
- NCT05225220
- Testing
- Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Casa Colina Hospital and Centers for Healthcare
ME/CFS, Long COVID
LIFT: Life Improvement Trial
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus…
- Conditions
- ME/CFS, Long COVID, PASC
- Trial name
- LIFT (NCT06366724)
- Testing
- Pyridostigmine, Low-Dose Naltrexone
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Covid19, Neurocognitive Dysfunction
Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.
Long-term neurocognitive and psychiatric consequences of COVID-19 remain mostly unknown to date. It has been reported that coronaviruses cause direct central nervous system infection (Needham et al. 2020).
- Trial name
- NPQCOVID (NCT05019300)
- Testing
- Exposure: COVID-19 severity
- Where
- Chile
- Volunteers
- 80 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical…
- Trial name
- NCT06739668
- Testing
- Pascal device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog")…
- Trial name
- PAISE-AriSE (NCT07714213)
- Testing
- Aripiprazole (low-dose, 1mg)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Christiana Franke
Fatigue, Dyspnea
TaiChi-DTx for Treating Long Covid Symptoms
The randomized controlled trial will be conducted to evaluate the effectiveness of a Multi-domain Tai Chi Digital Therapy for treating the individuals suffering from the long term COVID-19 syndrome (Long COVID).
- Conditions
- Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
- Trial name
- TaiChi-DTx (NCT05419219)
- Testing
- the multi-domain Tai Chi Digital therapy Software Application
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tim Shi
Covid19, Neurocognitive Dysfunction
Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain…
- Trial name
- HBOTpCOVID (NCT04647656)
- Testing
- Hyperbaric oxygen
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- Assaf-Harofeh Medical Center
Traumatic Brain Injury (TBI), Acquired Brain Injury
LearningRx Cognitive Training for Brain Injury
The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain…
- Conditions
- Traumatic Brain Injury (TBI), Acquired Brain Injury, Post COVID-19 Cognitive Impairment
- Trial name
- NCT02918994
- Testing
- LearningRx cognitive training
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
Covid19
Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
- Trial name
- NCT04860869
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Cognitive Decline, COVID-19
Hyperbaric Oxygen Therapy Improves Brain Function in Patients With Cognitive Decline After COVID-19 Infection.
COVID-19 has swept the world, and while some people may experience long-term cognitive decline as a result of infection, no effective treatment has been announced.
- Conditions
- Cognitive Decline, COVID-19, SARS CoV 2 Infection
- Trial name
- NCT05715801
- Testing
- hyperbaric oxygen therapy, conventional oxygen therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University